Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Seven Patent Applications Related to RNAi: Nov 1, 2007

Premium
Title: Potent Inhibition of Influenza Virus by Specifically Designed Short Interfering RNA
 
Number: 7,288,531
 
Filed: Feb. 15, 2007
 
Lead Inventor: Bijay Pal, California State Polytechnic University
 
The patent, its abstract states, “discloses siRNA sequences against the constant region of the influenza virus nucleoprotein gene.” The invention further includes one or more of defined siRNA sequences in the form of “an aqueous suspension suitable for nasal inhalation. Still further, the invention includes one or more of said siRNA sequences in the form of a plasmid expressing intracellularly in animals including humans.
 
“In another aspect, the invention includes one or more of said siRNA sequences in the form of an AAV vector adapted to express intercellularly and establish a permanent inhibitory effect against influenza virus by integrating to the cellular chromosome of animals including humans,” the abstracts adds. “The invention also includes the administration to an animal including humans, in a therapeutically effective amount, at least one of said siRNA sequences.”
 

 
Title: Methods to Treat or Prevent Hormone-Resistant Prostate Cancer Using siRNA Specific for Protocadherin-PC, or Other Inhibitors of Protocadherin-PC Expression or Activity
 
Number: 20070248535
 
Filed: Feb. 7, 2006
 
Lead Inventor: Ralph Buttyan, Columbia University
 
“The invention is directed to compounds and methods for treating or preventing hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity, including antisense oligonucleotides and antibodies,” the patent application’s abstract states. “The invention also provides for the use of protocadherin-PC as an in vivo prostate cancer biomarker, and includes a kit for detecting prostate cancer in biological samples. Also covered by the invention is a transgenic non-human mammal engineered to overexpress protocadherin-PC specifically in the prostate.”
 

 
Title: Arrays Containing Cleavable RNAi Molecules
 
Number: 20070248960
 
Filed: April 19, 2006
 
Inventor: Dianne Rees, Agilent
 
The patent application, according to its abstract, claims “a nucleic acid array ... [comprising] a substrate and an array of features on a surface of the substrate … [including] interfering RNA molecules that are linked to the surface of the substrate by a cleavable linker.”
 

 
Title: Compositions and Methods for Altering RNAi
 
Number: 20070249009
 
Filed: Dec. 19, 2006
 
Inventor: Richard Carthew, Northwestern University
 
The invention “relates to compositions and methods for altering (e.g., enhancing) RNAi,” the patent application’s abstract states. “In particular, the … invention provides systems and methods for identifying regulators of RNAi. For example, the … invention provides RNAi regulators (e.g., HPS1 and HPS4) and methods of … inhibiting these regulators in order to … enhance RNAi. The … invention also provides methods of identifying inhibitors … of RNAi regulators and methods of using the same … to enhance RNAi.
 
“Compositions and methods of the … invention find use in research (e.g., functional genomics), therapeutic (e.g., drug discovery and delivery), and clinical applications,” the abstract adds.
 

 
Title: Compounds and Methods for RNA Interference of the P65 Subunit of NF-Kappa-B
 
Number: 20070249549
 
Filed: Dec. 17, 2004 PCT Filed: Dec. 17, 2004
 
Inventor: Lars-Goran Axelsson, Index Pharmaceuticals
 
“This invention relates to compounds, compositions, and methods useful for modulating the expression and activity of NF-kappa-B by RNA interference using small nucleic acid molecules, such as short interfering nucleic acid, short interfering RNA and double-stranded RNA,” the patent application’s abstract states. “Furthermore the invention provides methods for preventing, treating, or alleviating NF-kappa-B dependent diseases whereby NF-kappa-B is believed to play a role in the pathogenesis of a disease in a subject, preferably a human, by administration of a therapeutic effective and in a pharmacologically accepted form, the siRNA compounds of the invention.”
 

 
Title: Compositions and Methods for siRNA Inhibition of Primate Polyomavirus Gene
 
Number: 20070249552
 
Filed: May 12, 2005 PCT Filed: May 12, 2005
 
Inventor: Kamel Khalili, Temple University School of Medicine
 
According to the patent application’s abstract, “RNA interference using small interfering RNAs [that] are specific for mRNA produced from the JCV agnoprotein and large T antigen genes inhibits expression of these and other primate polyomavirus genes. Primate polyomavirus infection, and diseases which are associated with primate polyomavirus infection, can be treated by administering the small interfering RNAs.”
 

 
Title: siRNA Targeting WEE1 Homolog
 
Number: 20070249819
 
Filed: June 12, 2007
 
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
 
“Efficient sequence specific gene silencing is possible through the use of siRNA technology,” the patent application’s abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to WEE1.”
 

 
Title: Small RNA Purification
 
Number: 20070249821
 
Filed: March 8, 2007
 
Lead Inventor: Rex Bitner, Promega
 
The invention relates to “methods, kits, and compositions for purifying small RNA molecules,” according to the patent application’s abstract. “In particular, the … invention provides methods for purifying small RNA molecules from a sample containing both small RNA molecules and larger RNA molecules using a compaction agent and a RNA binding matrix, as well as compositions and kits for practicing such methods. In certain embodiments, the compaction agent comprises a plurality of metal-amine-halide molecules.”

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.